Immune system protein
POPULARITY
Categories
So last weeks show had an easter egg, unknown even to me. Apparently (and thank you to those who emailed me) one of the bands from last week don't actually exist. So along with the great music you get to hear me philosophise on AI and music. There may be more little chats like this over the next few weeks. But brief. Because we're here for the music, not the sermons! Antibody & Binary Division & Czarina - My Enemy (Vioflesh) cut.rate.box - Fireshine Synpasyche - Blindness SynthAttack - Immortal NZM 99 - Revenge Alienare - Let This Moment Never End Incendie - Decaying Realities (Soj) Touching The Void - Fragment (Substaat) http://synthetic.org/ https://www.youtube.com/@RealSyntheticAudio
Featuring an interview with Dr Kevin Kalinsky, including the following topics: Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00) Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006. Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04) Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02. BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53) Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO. Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35) Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract CME information and select publications
In the final episode of this two-part series, Dr. Justin Abbatemarco discusses long-term maintenance therapy options. Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200504
In part one of this two-part series, Dr. Justin Abbatemarco discusses what we know and don't know surrounding MOG antibody–associated diseases (MOGADs). Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200504
Style and Stewardship - Intentional Living, Spiritual Growth, Wellness, Nutrition, Lifestyle
Exploring Germ Theory, Alternative Health, and Scientific Perspectives.In this episode of the Style and Stewardship podcast, Cher of Style and Stewardship interviews Dr. Tom Cowan, who discusses the importance of asking the right questions in wellness and health. They delve into the concepts of terrain theory versus germ theory, emphasizing the role of nutrition and personal agency in health. Dr. Cowan shares insights on how to approach health holistically, the significance of understanding food sensitivities, and the need for common sense in medical practices. The conversation encourages listeners to take control of their health and question conventional medical narratives.TakeawaysAsking good questions leads to better health outcomes.Healthy plants are not eaten by insects.Terrain theory emphasizes the importance of health over germs.There is no scientific evidence for the existence of viruses.Personal agency is crucial in health management.Nutrition plays a vital role in overall wellness.Avoiding processed foods is essential for health.Common sense approaches to health are often overlooked.Understanding food sensitivities can improve health.Vaccines should be approached with caution.Guest's Bio continued and helpful links:Dr. Cowan continues to actively lecture and interview, sharing information via his website, DrTomCowan.com, where he also offers many of the products he has used personally and in his practice. Additionally, Dr. Cowan offers high-quality beyond-organic vegetable powders, pantry and pasture products on his DrCowansGarden.com website, health and wellness support services at NewBiologyClinic.com, and educational opportunities for practitioners and others at NewBiologyCurriculum.com. Dr. Cowan lives with his wife, Lynda, on rural farmland in Upstate New York. He has three children, one stepson and seven thriving grandchildren. Conversations with Dr. Cowan and Friends PodcastThis episode is a conversation exploring different perspectives on health and science and does not provide medical advice.I'm Cher, a Certified Holistic Nutritionist who strives to educate and encourage you to be an intentional steward of your health and lifestyle. Work with Me: https://my.practicebetter.io/#/615b0f213980330c58fb3a87/bookings?step=servicesBook a Free Call: https://tinyurl.com/5a3nk245Discounted High-Quality Supplements https://us.fullscript.com/welcome/styleandstewardship/store-startContact#styleandstewardship #stewardship #holistichealth Chapters- Timestamps00:00 Introduction to Wellness and Questions02:45 Exploring Willard Water05:33 Gardening Insights and Plant Health11:36 Understanding Terrain Theory17:28 Challenging Germ Theory23:23 The Concept of Immunity29:11 Antibodies and Autoimmune Diseases34:36 The Question of Antibody Specificity37:59 Understanding Health and Wellness38:45 Taking Agency in Health41:31 The Four Reasons for Illness53:01 Personalized Nutrition and Food Sensitivities59:51 The Importance of Listening to Your Body01:07:38 Tom Cowan's Daily Nourishment
Is Low Dose Naltrexone (LDN) the answer for lowering thyroid antibodies?This episode explores the real benefits and limitations of LDN for autoimmune conditions like Hashimoto's and Graves' disease. I share what the research actually says, why results are mixed, and why LDN should never replace the foundations of thyroid healing.Listen in to get clarity before deciding if this option makes sense for you.00:00 – Episode Preview00:59 – Podcast Introduction01:23 – How Low Dose Naltrexone Works03:38 – What the Research Says About LDN05:14 – Benefits: Immune Modulation, Safety, and Access06:31 – Downsides: Side Effects, False Hope, and Limitations09:02 – Patient Experiences: Why Results Vary Widely10:27 – Risk vs. Benefit Before Permanent Treatments11:50 – Dr. Eric's Masterclass Invitation13:28 – Podcast Outro13:49 – Final Thoughts: LDN in Graves' vs. Hashimoto'sMentioned in this Episode: https://savemythyroid.com/masterclass To take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' sHave you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksC...
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here.
Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593. Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications
In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe interview Asst. Professor Pin-Kuang Lai from Stevens Institute of Technology about his keynote speech at AAPS NBC 2025 and the intersection of AI and molecular engineering, particularly in predicting the viscosity of monoclonal antibodies. They discuss the challenges of high concentration formulations, the importance of AI validation, and the future of formulation development. Lai shares insights from his international research journey and collaborations with pharmaceutical companies, as well as opportunities for students interested in this field.00:00 Preview & Intro01:58 Deep Viscosity and AI in Antibody Development04:39 AI Validation and Model Reliability07:12 International Journey and Collaborative Research08:42 Future of Formulation Development10:30 AAPS NBC Experience11:30 Academic vs. Industry Career Paths12:31 Collaboration with Pharmaceutical Companies13:59 Modeling Protein Aggregation Challenges14:43 Student Engagement and Research Opportunities15:45 Expanding Applications of Machine LearningDr. Pin-Kuang Laihttps://www.linkedin.com/in/pin-kuang-lai/ Stevens Institute of Technology - https://www.stevens.edu/ Dr. Lai's Publications - https://www.linkedin.com/in/pin-kuang-lai/details/publications/ The DeepViscosity Model - https://devpred.onrender.com/DeepViscosityDr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/
In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamabMonitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamigPresenters: Dr Christopher Flowers Division Head, Division of Cancer MedicineChair, Professor, Department of Lymphoma/MyelomaJohn Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer MedicineMD Anderson Cancer CenterHouston, TexasDr John AllanAssociate Professor of Clinical MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by Regeneron Pharmaceuticals, Inc.
Tolaney focuses on advancing breast cancer treatment through innovative clinical research. She has been instrumental in developing novel therapies and leading key clinical trials, particularly for early-stage HER2-positive breast cancer. Timestamps 00:09 – Introduction 01:12 – What is HER2-positive breast cancer? 03:00 – Key trials Tolaney has led 07:16 – Antibody-drug conjugates 12:00 - Breast Oncology Guidelines 14:51 – Treatment optimisation 18:27 – Equity in healthcare 21:10 – Mentoring the next generation of oncologists 22:52 – Tolaney's wishes for healthcare
Episode 19 of onAIRR features a lively and insightful conversation with three outstanding scientists committed to advancing pandemic preparedness. Dr. Lauren Williamson and Dr. Robert Carnahan, both from Vanderbilt University Medical Center, and Dr. Matthew Vogt, from the University of North Carolina, share their passion for viral immunology and the art of discovering and developing therapeutic antibodies. onAIRR's guests provide a behind-the-scenes look at how collaborative research is shaping the future of global health. They introduce the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) research network, a major NIH-funded initiative aimed at strengthening pandemic readiness. The conversation explores the use of prototype pathogen approaches to identifying broadly neutralizing antibodies against high-priority viral families, the challenges of balancing breadth versus potency in therapeutic antibodies, and innovative screening methodologies that could transform our ability to respond to future pandemics. Comments are welcome to the inbox of onairr@airr-community.org or on social media under the tag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast. The episode is hosted by Dr. Ulrik Stervbo and Dr. Zhaoqing Ding. Announcements and links Lauren Williamson https://www.vumc.org/crowe-lab/person/lauren-williamson-phd Robert Carnahan https://www.vumc.org/crowe-lab/person/robert-carnahan-phd Matthew Vogt https://www.vogtviruslab.com ReVAMPP https://revampp.org ReVAMPP https://www.niaid.nih.gov/news-events/nih-awards-establish-pandemic-preparedness-research-network "Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness” https://doi.org/10.1093/infdis/jiac296 Adaptive Immune Receptor Repertoire Community (AIRR-C) https://www.airr-community.org The Antibody Society (TAbS) https://www.antibodysociety.org AIRR-C Seminar Series https://www.antibodysociety.org/the-airr-community/airr-community-seminar-series
Learn more about your ad choices. Visit megaphone.fm/adchoices
Could treatments many people consider ‘normal' dental procedures, like root canals or mercury fillings, impact your thyroid healing?This episode looks at how dental work might influence thyroid health. I'll explain what mercury amalgams are, why some people feel better after removing them, and why others do not. We'll also cover the debate around root canals and whether they can create ongoing immune stress. The focus isn't on quick fixes but on helping you think through risks and benefits so you can decide what makes the most sense for your healing journey.If your heightened antibodies haven't budged despite your best efforts, this could give you a new angle to explore. Tune in now!Episode Timeline: 00:00 – Episode Preview01:32 – Podcast Intro01:56 – Dental Work as a Hidden Trigger for Thyroid Antibodies03:45 – Mercury Amalgams: What They Are & Their Potential Impact06:07 – Root Canals, Bacteria, and Chronic Inflammation Concerns06:25 – Safe Removal & the Role of Biological Dentists09:14 – Comparing Risks: Mercury vs. Root Canals10:16 – Personal Experience with a Root Canal and Implant13:22 – Considerations for Removing Amalgams15:50 – Testing Options for Mercury and Immune Reactions21:50 – Why Antibodies Stay High and Next Steps to Consider22:08 – Podcast Outro22:29 – Bonus Notes: Gum Inflammation, Holistic vs. Biological Dentists, and a Nickel Allergy CaseMentioned In this Episode: Episode with Dr. Eric Kempter: https://savemythyroid.com/podcast/biological-dentistry-and-thyroid-health-with-dr-eric-kempter-064/ To take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' sHave you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksC...
Featuring an interview with Dr Erika Hamilton, including the following topics: Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract Management protocols for adverse events associated with sacituzumab govitecan (7:49) García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101. Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51) Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134. Sequencing ADCs in breast cancer (13:12) Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract CME information and select publications
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm. CME information and select publications here.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VFP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 18, 2026.Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VFP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 18, 2026.Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VFP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 18, 2026.Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VFP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 18, 2026.Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VFP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 18, 2026.Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
Join us this episode for a conversation with Norbert Weidner, MD, Professor and Chair of the Spinal Cord Injury Center at Heidelberg University Hospital. In this conversation we discuss results of the Neuroimmunophilin Nogo-A Antibody in Spinal Cord Injury (NISCI) trial, published in a paper titled "Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial" in the journal Lancet Neurology. In this paper Weidner and their NISCI team discuss the top-line findings from a large multi-center clinical trial where antibodies against Nogo-A were administered to the spinal space early after acquired SCI. We invite you to listen in as Dr. Weidner gives an insider perspective on the NISCI trial, and trust you will enjoy our conversation on intrathecal drug delivery in the acute phase of SCI.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VFP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 18, 2026.Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
Can you give patients one ADC after another? A renowned panel of experts interrogate this question and many more in this thought-provoking program. Credit available for this activity expires: 8/25/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002851?ecd=bdc_podcast_libsyn_mscpedu
Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Anonymous: Hi Dr. Cabral, My OATs test came back with normal markers for bacteria and fungus. I was on an extremely low carb diet when I took the test and was wondering if that could cause a false negative. I have taken herbal Antimicrobials and garlic in the past which sometimes eliminates the bloating and brain fog and does so within a few days but only at double doses and only working temporarily. I have a few mild chronic fungal infections, IBS, cognitive symptoms, and MCAS. Do you think the issue is more likely related to an overgrowth or intestinal permeability caused by MCAS? How should I begin treatment since I am sensitive to many supplements? My food sensitivity test unfortunately showed a false negative to all foods. Zonia: Hello Dr. Cabral, Thank you for all your insightful information! My husband has lipoma's all over his body ranging from dime size to 1/2 tennis ball. His mom has them too, but very few. He started getting them removed by the dozen and I understand they can regrow. How can we help prevent the regrowth? Also, we have twins (B/G)and are there any labs that can determine if either have the genes or how to minimize the chances they will have any? Thank you in advance! Chris: Hi Dr Cabral, regarding magnesium intake and supplemental H2: The tablets we have include 80 mg of magnesium for 8ppm H2. If you were going to rely on H2 tablets for your exclusive molecular hydrogen source, how many tablets would you take per day to maximize H2 benefits while maintaining advisable magnesium levels and not too much? Assuming 2 scoops of DNS at breakfast (50mg magnesium) + 2 Full Spectrum Magnesium caps at dinner (250mg). I've been varying from 1-3 H2 tablets/daily throughout the week. I stopped taking a scoop of your very delicious & effective Calming Magnesium before bed (300mg) in order to prioritize the benefits of Molecular Hydrogen, however, would love to add this back in if its not too much Magnesium with everything else. Thank you always. Anonymous: Hi! I have a couple questions. Might have to submit two for the length. First is about thyroid. My thyroid labs are showing normal TSH .56, low free T4 1.33, low total T3 114, high reverse T3 17.20 & TPO high at 25. Does this indicate Hashimoto hypothyroidism? Is this fixable or will I be on supplements or meds for ever? Is TPO specific to the thyroid or is this indicative of autoimmune issues in general? Im curious what even causes these issues to begin with Thank you so much! Anonymous: Hi again, 2nd question. I have a hard time gaining muscle & showing tone. I'm a petite person, and have never really shown muscle tone even in high school despite being in sports.After my third baby I lost muscle. I can tell by my body composition changes.I weigh less but look and feel like it's no muscle & more fat. A PT once was shocked at my glute weakness comparing it to the elder. If I ever take a break in exercising, for about two weeks or more I feel much weaker than before I even started, seems like my strength is decreasing rapidly if I get sedentary for even 2 weeks. Could this have an underlying cause or is this just how some of us are? Should I accept the fact that maybe I won't ever build or show much muscle tone? For reference, 33 y/o female, possible hashimotos and lipedema. Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3488 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from August 16-22 2025.
Antibody-drug conjugates (ADCs) are a relatively new type of medicine for breast cancer. Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Dato-DXd (brand name: Datroway) are two ADCs used to treat breast cancer. Dr Benjamin Schrank and colleagues have developed a new type of ADC that combines an antibody with a toxin — called an antibody-toxin conjugate — that teaches the immune system to recognize and attack cancer cells. Listen to the episode to hear Dr. Schrank explain: the antibody and the toxin component of the medicine how the new medicine works possible side effects next steps for the research Episode image photo credit: The University of Texas MD Anderson Cancer Center
In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field. Timestamps 00:00 – Introduction 02:50 – What initially drew Komal into oncology 04:45 – The future of breast cancer care 06:13 – Possibility of personalised treatments for patients 07:40 – Antibody-drug conjugates 09:30 – How we define HER2 status 14:40 – HER2-low disease 17:40 – Targeted therapy combinations 20:54 – Endocrine resistance 23:18 – The realities of implementing new therapies 28:40 – Promising initiatives on the horizon 31:30 – Komal's key takeaways
If you've ever been told your labs are “normal” but you still feel exhausted, foggy, or off, this episode is your game-changer. In Part 2 of our conversation with thyroid expert McCall McPherson, we go beyond the basics and dive into how to actually understand your lab results, and why so many women are dismissed or misdiagnosed because their numbers fall within outdated, generic ranges. Maria opens up about her own thyroid test results, and McCall breaks it all down: what's truly considered optimal (not just “in range”), what your TSH, T3, and antibodies are really saying, and how understanding your labs can help you take back your energy, mood, metabolism, and more. Because when you can read your labs like a thyroid expert, you stop guessing… and start healing smarter!! HEALERS & HEAL-LINERS: "Normal" isn't optimal. Most lab ranges are based on averages of unwell people, which means you can feel awful and still be told you're "fine." True healing begins with optimal, not just acceptable. Your labs are a roadmap. TSH alone won't tell the full story. Understanding markers like Free T3, Free T4, Reverse T3, and antibodies can unlock the real reason you feel off and guide you toward real solutions. You can influence your results. Antibody levels can be improved with lifestyle changes. Tracking your labs over time empowers you to measure progress, reduce inflammation, and protect your thyroid health long-term. HEAL SQUAD SOCIALS IG: https://www.instagram.com/healsquad/ TikTok: https://www.tiktok.com/@healsquadxmaria HEAL SQUAD RESOURCES: Heal Squad Website:https://www.healsquad.com/ Heal Squad x Patreon: https://www.patreon.com/HealSquad/membership Maria Menounos Website: https://www.mariamenounos.com My Curated Macy's Page: Shop My Macy's Storefront Prenuvo: Prenuvo.com/MARIA for $300 off EMR-Tek Red Light: https://emr-tek.com/discount/Maria30 for 30% off Airbnb: https://www.airbnb.com/ Join In-Person Heal Retreat Waitlist! https://mariamenounos.myflodesk.com/heal-retreat-waitlist GUEST RESOURCES: Instagram: https://www.instagram.com/mccallmcphersonpa https://www.instagram.com/modernthyroid Website: https://www.modernthyroidclinic.com/ Thyroid Lab Guide: https://gift.modernthyroidclinic.com/ ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content (published or distributed by or on behalf of Maria Menounos or http://Mariamenounos.com and http://healsquad.com) is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions. This podcast is presented for exploratory purposes only. Published content is not intended to be used for preventing, diagnosing, or treating a specific illness. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.
A fluffy, long-necked cousin of the camel might be the key to protecting against…
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.
Featuring an interview with Dr Jacob Sands, including the following topics: TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00) Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52) Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599. Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500. Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26) Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11. CME information and select publications
Cindy talks with Shane Crotty about his teenage days driving 3 ½ hours every weekend to have his first research experience in marine biology, how that eventually led to studying how vaccines work and how we can make them better, and how immunology research and publishing got a turbo-boost during the pandemic. Hosts: Cindy Leifer Guest: Shane Crotty Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Immune 85 discusses Crotty lab paper on human upper airway immunity Shane Crotty on TWiV657 SARS-CoV-2 immunity Shane Crotty on TWiV684 Persistence of SARS-CoV memory Shane on TWiV802 Another epitope Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.
August 12, 2025 | Diagonal Therapeutics founder and CEO Alexey Lugovskoy discusses the key lessons learned over his illustrious career, starting from his childhood in the Soviet Union to founding his own company, Diagonal Therapeutics. With host Tariq Ghayur, Lugovskoy shares insights gained from working with organizations of different sizes, taking on the obstacles of building a pipeline, and integrating AI/ML into discovery programs, as well as his most memorable achievement—and most memorable failure. He also offers advice to young scientists and entrepreneurs, emphasizing the importance of challenging problems and surrounding yourself with the right people.
Are you having persistent Hashimoto's symptoms even after being on Thyroid medications? Are you wondering why your Antibody levels are stubbornly high?Feeling brain fogged, tired all day?Then, this episode on The Link Between EBV Activation & Autoimmune Conditions can be an eye-opener for you.Connect With Me -Instagram - https://www.instagram.com/anshulguptamd/Twitter - https://www.twitter.com/anshulguptamdFacebook - https://www.facebook.com/drguptafunctPinterest - https://www.pinterest.com/anshulguptamdTo Buy Good Quality Supplements Goto -https://functionalwellbeingshop.com/Work With Me -https://www.anshulguptamd.com/work-with-me/Take The Thyroid Quiz & Evaluate Your Thyroid Health -https://www.anshulguptamd.com/thyroid-quiz/About Dr.Anshul Gupta MD -Dr. Anshul Gupta Md Is a Board-certified Family Medicine Physician, With Advanced Certification In Functional Medicine, Peptide Therapy, And Also Fellowship training in Integrative Medicine. He Has Worked At The Prestigious Cleveland Clinic Department Of Functional Medicine As Staff Physician Alongside Dr. Mark Hyman. He Believes In Empowering His Patients To Take Control Of Their Health And Partners With Them In Their Healing Journey.He Now Specializes As A Thyroid Functional Medicine Doctor, And Help People Reverse Their Unresolved Symptoms Of Thyroid Dysfunction.
Aron Knickerbocker, President and CEO of Aulos Bioscience, is on a mission to extend the lives of cancer patients through safer and more effective immunotherapy using AI and machine learning to accelerate drug discovery and optimization. The company's lead drug candidate is an antibody that was designed using AI to harness the power of interleukin-2 to activate the immune system against tumors. The advantages of AU-007 over previous IL-2 therapies include the ability to selectively activate tumor-fighting immune cells while avoiding toxicity due to vascular leakage. Current trials are underway in advanced melanoma and non-small cell lung cancer, which are showing the potential for durable responses and immune memory. Aron explains, "So Aulos has really been founded to carry out a mission to extend the lives of patients with innovative, safe, and ultimately effective cancer immunotherapy. And you mentioned IL-2, which is the naturally occurring protein that we're seeking to harness and redirect in productive ways to help the patients. And this has really been kind of a driver for me over the years, wanting to improve on cancer patient care. This is a company with an important mission and a great team, and our program is really interesting. It's harnessing IL-2 in such a way that it sends it to the cells that are capable of attacking the tumor and killing the tumor cells, and keeps it away from the cells that suppress the immune response. It's really kind of using a double-edged sword in a productive way to help patients with cancer." "So this is the first antibody to go into human clinical trials. It was designed in part by leveraging an AI platform, as you noted. And that platform was created by our collaborators at Biologic Design. They're the company that created this molecule. And what biologic design does is essentially using an AI system that has machine learning algorithms that drive it. It mimics what the immune system does normally. So when we get sick and we need to make antibodies to something, our immune system says, Do I already have something that will kind of bind to the target or the virus or whatever it's trying to hit? And then it will optimize that. It will go through a process of rapid change. And what the AI system and the machine learning algorithms that have been trained on millions of antibodies in the targets to which they bind do is recognize patterns much like an AI chatbot might recognize language patterns." #AulosBio #Antibodies #MedAi #AI #IL2 #Onocology #Cancer #NSCLC #AdvancedCutaneousMelanoma #DrugDiscovery #BiologicDesign #Tregs aulosbio.com Download the transcript here
Aron Knickerbocker, President and CEO of Aulos Bioscience, is on a mission to extend the lives of cancer patients through safer and more effective immunotherapy using AI and machine learning to accelerate drug discovery and optimization. The company's lead drug candidate is an antibody that was designed using AI to harness the power of interleukin-2 to activate the immune system against tumors. The advantages of AU-007 over previous IL-2 therapies include the ability to selectively activate tumor-fighting immune cells while avoiding toxicity due to vascular leakage. Current trials are underway in advanced melanoma and non-small cell lung cancer, which are showing the potential for durable responses and immune memory. Aron explains, "So Aulos has really been founded to carry out a mission to extend the lives of patients with innovative, safe, and ultimately effective cancer immunotherapy. And you mentioned IL-2, which is the naturally occurring protein that we're seeking to harness and redirect in productive ways to help the patients. And this has really been kind of a driver for me over the years, wanting to improve on cancer patient care. This is a company with an important mission and a great team, and our program is really interesting. It's harnessing IL-2 in such a way that it sends it to the cells that are capable of attacking the tumor and killing the tumor cells, and keeps it away from the cells that suppress the immune response. It's really kind of using a double-edged sword in a productive way to help patients with cancer." "So this is the first antibody to go into human clinical trials. It was designed in part by leveraging an AI platform, as you noted. And that platform was created by our collaborators at Biologic Design. They're the company that created this molecule. And what biologic design does is essentially using an AI system that has machine learning algorithms that drive it. It mimics what the immune system does normally. So when we get sick and we need to make antibodies to something, our immune system says, Do I already have something that will kind of bind to the target or the virus or whatever it's trying to hit? And then it will optimize that. It will go through a process of rapid change. And what the AI system and the machine learning algorithms that have been trained on millions of antibodies in the targets to which they bind do is recognize patterns much like an AI chatbot might recognize language patterns." #AulosBio #Antibodies #MedAi #AI #IL2 #Onocology #Cancer #NSCLC #AdvancedCutaneousMelanoma #DrugDiscovery #BiologicDesign #Tregs aulosbio.com Listen to the podcast here
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. CME information and select publications here.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.
Featuring an interview with Dr Erika Hamilton, including the following topics: Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00) Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025. First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02) Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109. Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06) Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53) Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019. Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104. Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004. CME information and select publications
“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
TWiV explains a cohort study of over one million Danish children which shows no evidence supporting an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders associated with early childhood exposure to vaccines with aluminum-base adjuvants, and a study of antibodies induced by mRNA-1273 and NVX-CoV2373 COVID-19 vaccines which show that polyclonal antibodies against a single site on the spike N-terminal domain show immunodominance, high diversity, and limited cross-reactivity, indicating the need to direct antibody responses away from this site. Hosts: Vincent Racaniello, Alan Dove, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV No chronic effects of aluminum-based adjuvants in vaccines (Ann Int Med) Aluminum in vaccines (CHOP) Structural serology of antibody responses to COVID vaccines (Cell Rep) Letters read on TWiV 1239 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – MHC Class I Antigen Presentation Video Alan – We Become What We Behold Vincent – New Injectable Recommended by Europe for HIV Prevention Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
Her antibodies were high, her gut was off and surgery was on the table. So she started asking what was really driving her symptoms.Alexandria was told she had the antibodies for both Graves' and Hashimoto's in 2017 and initially followed conventional advice, including methimazole. But after facing the possibility of thyroid removal, she explores deeper root causes. This health audit traces the progress she's made with dietary changes, gut support, and lifestyle shifts and the imminent questions as she prepares for a future pregnancy. We discuss why her antibody levels dropped, where she's still seeing symptoms, and what steps might help her move forward without fully relying on medication.Managing your thyroid but curious about alternative support options? Listen to this episode!Episode Timeline: 00:00 – Episode Overview01:44 – Podcast Intro02:16 – Meet Alexa and her Diagnosis 03:00 – Seeking Alternatives to Thyroid Removal04:42 – Impact of gluten-free and AIP diets06:00 – Goiter changes with diet06:44 – Dairy and food tradeoffs07:14 – Antibody testing history08:03 – Gut support: HCl, Rifaximin, colostrum09:18 – SIBO diagnosis and food sensitivities10:42 – Gluten, permeability, and testing limitations11:33 – Lifelong gut issues and acid blocker use13:23 – Apple cider vinegar and digestive strategies15:19 – Pregnancy while on medication16:00 – Detox planning before conception18:32 – Stool test, travel, and GI infections19:19 – SIBO, food poisoning, and motility damage22:16 – AIP next steps and testing decisions23:52 – Podcast Outro24:13 – Final Thoughts and RecommendationsFree resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid?Click Here to access hundreds of free articles and blog posts.Click Here for Dr. Eric's YouTube channelClick Here to join Dr. Eric's Graves' disease and Hashimoto's groupClick Here to take the Thyroid Saving Score Quiz Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksClick Here to work with Dr. Eric
In this episode, Marc Elia, Chairperson of the Board at Invivyd, discusses his personal experience with COVID-19 and long COVID, the company's unique monoclonal antibody platform, and how Invivyd is working to address persistent gaps in infectious disease prevention and care. He also highlights the importance of patient voices in regulatory processes and the future of scalable, accessible monoclonal antibody therapies.This episode is sponsored by Invivyd.